69 related articles for article (PubMed ID: 36937854)
1. BUB1 Promotes Gemcitabine Resistance in Pancreatic Cancer Cells by Inhibiting Ferroptosis.
Wang W; Zhou X; Kong L; Pan Z; Chen G
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672622
[TBL] [Abstract][Full Text] [Related]
2. The ethyl acetate extract of
Hasibuan PAZ; Keliat JM; Lubis MF; Nasution A
Saudi Pharm J; 2024 Jan; 32(1):101872. PubMed ID: 38111670
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect and related mechanism of decitabine combined with gemcitabine on proliferation of NK/T cell lymphoma cells.
Lin L; Liu X; Yu H; Deng H; Peng K; Chen J; Zhang C; Jiang T; Liu X
Front Pharmacol; 2023; 14():1134895. PubMed ID: 36937854
[No Abstract] [Full Text] [Related]
4. [Effects of Decitabine Combined with Bortezomib on the Proliferation of Mantle Cell Lymphoma Cell Lines and Its Underling Mechanisms].
Zhang JN; Qiao SK; Chen D; Xing LN; Li Y; Guo XN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1197-1204. PubMed ID: 32798398
[TBL] [Abstract][Full Text] [Related]
5. [Synergistic Antitumor Effect of Everolimus Combined with Gemcitabine on Diffuse Large B-Cell Lymphoma].
Zuo XQ; Tan CL; Li XM; Ma T
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):81-88. PubMed ID: 36765481
[TBL] [Abstract][Full Text] [Related]
6. Combination of Gemcitabine and Thymosin alpha 1 exhibit a better anti-tumor effect on nasal natural killer/T-cell lymphoma.
Chen M; Jiang Y; Cai X; Lu X; Chao H
Int Immunopharmacol; 2021 Sep; 98():107829. PubMed ID: 34119916
[TBL] [Abstract][Full Text] [Related]
7. [Mechanism of Sorafenib and Decitabine Inducing Apoptosis of Diffuse Large B-Cell Lymphoma Cells].
Zhou Y; Wang X; An YH; Sun WDBMCBAPC; Tong XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):146-152. PubMed ID: 32027268
[TBL] [Abstract][Full Text] [Related]
8. IL-10 contributes to gemcitabine resistance in extranodal NK/T-cell lymphoma cells via ABCC4.
Huo J; Fu L; Jin M; Li Z; Zhang M
Invest New Drugs; 2022 Jun; 40(3):537-545. PubMed ID: 35226228
[TBL] [Abstract][Full Text] [Related]
9. Augmenting chemotherapy with low-dose decitabine through an immune-independent mechanism.
Gutierrez WR; Scherer A; Rytlewski JD; Laverty EA; Sheehan AP; McGivney GR; Brockman QR; Knepper-Adrian V; Roughton GA; Quelle DE; Gordon DJ; Monga V; Dodd RD
JCI Insight; 2022 Nov; 7(22):. PubMed ID: 36227698
[TBL] [Abstract][Full Text] [Related]
10. Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial.
Zhang Y; Chen L; Hu GQ; Zhang N; Zhu XD; Yang KY; Jin F; Shi M; Chen YP; Hu WH; Cheng ZB; Wang SY; Tian Y; Wang XC; Sun Y; Li JG; Li WF; Li YH; Mao YP; Zhou GQ; Sun R; Liu X; Guo R; Long GX; Liang SQ; Li L; Huang J; Long JH; Zang J; Liu QD; Zou L; Su QF; Zheng BM; Xiao Y; Guo Y; Han F; Mo HY; Lv JW; Du XJ; Xu C; Liu N; Li YQ; Xie FY; Sun Y; Ma J; Tang LL
J Clin Oncol; 2022 Aug; 40(22):2420-2425. PubMed ID: 35709465
[No Abstract] [Full Text] [Related]
11. Epstein-Barr virus latency programs dynamically sensitize B cells to ferroptosis.
Burton EM; Voyer J; Gewurz BE
Proc Natl Acad Sci U S A; 2022 Mar; 119(11):e2118300119. PubMed ID: 35275790
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and tumour microenvironment influence of decitabine plus R-CHOP in patients with newly diagnosed diffuse large B-Cell lymphoma: Phase 1/2 and biomarker study.
Zhang MC; Fang Y; Xu PP; Dong L; Shen R; Huang YH; Fu D; Yan ZX; Cheng S; Jiang XF; Song Q; He Y; Zhao Y; Lu M; Ye J; Liu F; Cheng L; Wang CF; Wang L; Zhao WL
Clin Transl Med; 2021 Dec; 11(12):e584. PubMed ID: 34923760
[No Abstract] [Full Text] [Related]
13. Primary colon natural killer (NK)/T-cell lymphoma, nasal type, with perforations: a case report and literature review.
Xie Y; Liu Y; Wen C; Li W; Lu X; Deng L
Ann Palliat Med; 2021 Nov; 10(11):12025-12033. PubMed ID: 34872326
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
